ETFs Scienture Holdings, Inc.

SCNX

US80880X2036

Pharmaceuticals

Real-time Estimate Cboe BZX 14:39:23 2026-10-20 EDT			5-day change	1st Jan Change
3.025 ^USD	+3.60%		-6.48%	-76.24%

08-13	Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg	CI

ETFs positioned on Scienture Holdings, Inc.

Name		YTD change	Weight	AuM
UPAR ULTRA RISK PARITY ETF - USD		-1.23%	0%	59 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD		+11.76%	-.--%	513 M€

Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Employees

Sector

Pharmaceuticals

More about the company